Molecular Partners AG Advances its DARPin Pipeline at AACR 2026

Molecular Partners AG (ticker MPG on the SIX Swiss Exchange) announced a series of new pre‑clinical data points during its presentation at the American Association for Cancer Research (AACR) conference in Philadelphia on 19 April 2026. The company showcased three poster sessions, the most noteworthy of which highlighted the first logic‑gated Switch‑DARPin T‑cell engager, MP0632, and the novel DLL3‑targeted Radio‑DARPin, MP0712.

Breakthrough in Switch‑DARPin Technology

The MP0632 poster demonstrated that this engineered ankyrin repeat protein can selectively engage T‑cells only in the presence of a target antigen, thereby offering a safety advantage over conventional bispecific antibodies. Early‑stage tumor‑bearing mouse models revealed a significant reduction in tumor burden with minimal off‑target cytokine release, supporting the claim that MP0632 is the first Switch‑DARPin to achieve logic‑gated T‑cell activation in vivo. This development aligns with Molecular Partners’ strategy to leverage its proprietary DARPin platform across multiple therapeutic indications, including oncology, ophthalmology, and inflammatory diseases.

DLL3‑Targeted Radio‑DARPin MP0712

MP0712, a radiolabeled DARPin that targets DLL3—a protein overexpressed in small‑cell lung cancer and neuroendocrine tumors—was presented with data indicating superior tumor uptake and rapid clearance from healthy tissues. The preliminary safety profile in non‑human primates showed no evidence of off‑target radiation exposure. The company plans to advance MP0712 into phase I clinical trials within the next 12–18 months, positioning it as a potential companion diagnostic and therapeutic agent for DLL3‑positive malignancies.

Market Context and Investor Outlook

Despite a modest market cap of approximately CHF 131 million and a negative price‑earnings ratio of –1.96, Molecular Partners’ recent disclosures suggest a pivot toward translational readiness. The company’s close price of CHF 3.27 on 16 April 2026 reflects a valuation that remains highly sensitive to pre‑clinical milestones and regulatory approvals. Nonetheless, the unveiling of MP0632 and MP0712 at a high‑profile conference reinforces investor confidence in the DARPin platform’s scalability and therapeutic versatility.

Strategic Implications

  • Pipeline Expansion: The introduction of logic‑gated and radiolabeled DARPins expands the company’s portfolio into areas with high unmet medical need and limited therapeutic options.
  • Risk Mitigation: The selective activation mechanism of MP0632 potentially reduces the cytokine‑release syndrome risk that has plagued many T‑cell therapies.
  • Commercial Pathways: Successful clinical translation of MP0712 could open licensing opportunities with established oncology firms seeking novel targeted radiotherapeutics.

Forward‑Looking Perspective

Molecular Partners’ DARPin platform is poised to disrupt several therapeutic sectors. The current pre‑clinical successes serve as a strong foundation for clinical progression, and the company’s ongoing collaboration with academic and industry partners will likely accelerate the path to market. While valuation remains conservative, the strategic trajectory points toward a significant upside potential as the company moves from proof‑of‑concept to patient‑level validation.

For stakeholders monitoring the intersection of protein engineering and oncology, Molecular Partners’ latest AACR findings represent a critical milestone, underscoring the company’s capacity to translate innovative science into tangible therapeutic assets.